ArticleNeuropsychiatric disease and treatment2026
A Retrospective Chart Review of PTSD Symptoms in Military Servicemembers Participating in an Individually Guided Neuromodulation (Alpha-rTMS) Wellness Program.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Military members, particularly those who have been exposed to combat, face heightened risks of post-traumatic stress disorder (PTSD), which can significantly impair their overall quality of life. Current treatments are suboptimal, and despite published evidence, they do not provide therapy personalized to individual brain network activity. Materials and Methods: This is an uncontrolled open-label retrospective chart review of 94 active duty and retired servicemembers who self-reported symptoms related to PTSD. As part of the Operation Synchrony Program, participants received individually guided neuromodulation (α-rTMS) treatment, which was derived using a decision tree algorithm based on each participant's multivariate endogenous rhythms. The full treatment comprised α-rTMS sessions delivered 5 days a week, 30 minutes each, for a total of four weeks. Side effects and clinical assessments were collected including the PTSD Checklist for DSM-5 (PCL-5), Patient Health Questionnaire (PHQ-9), Rivermead Post-Concussion Symptoms Questionnaire (RPQ-16), and Brief Resilience Scale (BRS), administered at baseline, week-2, and week-4. This chart review protocol was approved under an exemption by WCG (Western IRB and Copernicus Group) IRB Study #1-1763934-1. Results: α-rTMS treatment was well-tolerated by participants, with no serious adverse events recorded. Average PCL-5 scores decreased significantly by a total of 48% from baseline ( Conclusion: Significant improvements in clinical symptoms were observed in this study. These results underscore the potential for α-rTMS treatment to address the gap in current treatment options by providing effective, safe, non-pharmacological treatment to reduce PTSD symptoms in military and civilian populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.